Barrick Mining Corporation Stock Price, News & Analysis

BioArctic AB (NASDAQ Stockholm: BIOA B) and partner Eisai presented compelling new data for lecanemab (Leqembi®) at AAIC 2025, showcasing significant treatment benefits over four years. The data demonstrated that lecanemab slows disease progression by approximately one year compared to no treatment over a four-year period.

Key findings include: 69% of early-stage patients showed improvement or no decline after four years of treatment, an 84% stability or improvement rate in real-world studies, and promising results for a new subcutaneous administration option. The safety profile remained consistent with previous studies, with decreased ARIA rates after initial 12 months.

The real-world study revealed high retention rates of 87%, with 20% of long-term patients improving from mild Alzheimer's to MCI. The new subcutaneous autoinjector showed comparable efficacy to IV administration while offering more convenient at-home treatment options.

ETQ, a subsidiary of Hexagon (HEXA), reported significant growth milestones in Q2 2025, expanding its customer base across multiple sectors including heavy industry, life sciences, and manufacturing. The company launched an enhanced version of its ETQ Reliance NXG® quality management system, featuring a new Quality Data Lake powered by Snowflake.

Key developments include new customer acquisitions such as AALTO HAPS and W.L. Gore, alongside expanded deployments with existing clients like A.O. Smith and Medline Industries. The company's annual quality survey revealed a strategic shift in manufacturing, with quality becoming a key driver of revenue growth. Additionally, ETQ will be part of Hexagon's planned spin-off 'Octave', expected to be completed in H1 2026.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai will present significant new data on Leqembi® (lecanemab) at the upcoming Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025.

Key presentations include four-year efficacy and safety data from the Phase 3 Clarity AD Open-Label Extension trial, new data on a subcutaneous formulation for maintenance dosing, and real-world case studies from U.S. clinical settings. Additionally, findings from cerebrospinal fluid samples using a novel immunoassay for measuring Aβ protofibrils will be presented.

Eisai leads the global development and regulatory submissions for Leqembi, with both Eisai and Biogen co-commercializing the product. BioArctic maintains commercialization rights in the Nordic region in partnership with Eisai.

Hexagon (HEXA) and Management Controls Inc. (MCi) have officially launched their integrated EcoSys + myTrack solution, combining Hexagon's EcoSys platform with MCi's myTrack platform. The integration aims to transform the management of shutdowns, turnarounds, and outages (STO) and capital projects.

The solution provides real-time cost and progress visibility by automating the collection and validation of contractor labor, equipment, and material data from the field. Key features include daily actuals tracking, SPI/CPI metrics within hours of shift completion, real-time vendor performance monitoring, and full alignment across scheduling and ERP systems.

The integrated solution, developed with FTI Consulting's implementation expertise, was initially unveiled at Hexagon LIVE Global 2025 in Las Vegas, targeting industries such as energy, chemicals, construction, and manufacturing.

Barrick Mining Corporation (NYSE:B) has announced it will release its Q2 2025 financial results on Monday, August 11, 2025, before market open at approximately 6:00 AM EDT. The company's President and CEO Mark Bristow will host a live presentation and webcast at 11:00 AM EDT, which will include a Q&A session with analysts.

The presentation materials will be accessible on Barrick's website, and the webinar recording will be available for later viewing.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received the 9th Bioindustry Award from the Japan Bioindustry Association for the drug discovery research of lecanemab (Leqembi®), an antibody treatment for early Alzheimer's disease.

The treatment, co-developed by BioArctic and Eisai, is based on Professor Lars Lannfelt's discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab works by binding to specific forms of amyloid-beta and helping clear it from the brain. Eisai leads the global development and regulatory submissions, with both Eisai and Biogen handling commercialization. BioArctic retains commercialization rights in the Nordic region in partnership with Eisai.

Hexagon US Federal (HEXA) has announced the divestiture of its Strategic Services & Solutions (HS3) business to Bart & Associates (B&A), as initially disclosed on July 2, 2025. This strategic move aims to streamline operations and sharpen focus on the company's core technology offerings.

The company will concentrate on delivering cutting-edge software, hardware, and value-added products supporting defense, intelligence, and federal-civilian missions across public safety, geospatial-intelligence, sensors & systems, and position, navigation, and timing (PNT). The HS3 business, known for providing IT services, geospatial services, and integrated solutions, will continue its federal government support under B&A's ownership.

Barrick Mining Corporation (NYSE:B) is advancing its $2 billion Super Pit Expansion Project at the Lumwana mine in Zambia, transforming it into a Tier One copper mine. The expansion will double copper production to 240,000 tonnes annually, supported by a 50 million tonne per annum processing plant.

Since 2019, Lumwana has contributed over $4 billion to Zambia's economy through taxes, royalties, procurement, and wages, with 79% ($3.4 billion) spent with local suppliers. The project includes development of Manyama township, an industrial supplier park, and a new regional airstrip. The mine employs 98% Zambian nationals and is implementing a REDD+ forest conservation program covering 300,000 hectares.

The operation is tracking well against its 2025 production guidance, with strong Q1 performance driven by increased plant throughput and improved open-pit efficiency.

SimScale and Hexagon (HEXA) have announced the general availability of Marc nonlinear finite element analysis (FEA) solver technology on the SimScale cloud platform. This integration allows engineers and design teams to access Marc's advanced nonlinear simulation capabilities directly through web browsers.

The cloud-native solution offers key features including fast nonlinear analysis, real-time collaboration, AI-powered workflows, High Performance Computing (HPC) scalability, and comprehensive multi-physics coverage. The technology is immediately available to SimScale's 700,000 Community users for limited free, non-commercial testing.